Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation

Circulation

Volumn 131, Issue 2, 2015, Pages 157-164

  Graham, David J ^a   Reichman, Marsha E ^a   Wernecke, Michael ^b   Zhang, Rongmei ^a   Southworth, Mary Ross ^a   Levenson, Mark ^a   Sheu, Ting Chang ^b   Mott, Katrina ^a   Goulding, Margie R ^a   Houstoun, Monika ^a   Macurdy, Thomas E ^b,c   Worrall, Chris ^d   Kelman, Jeffrey A ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Acumen LLC   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Centers for Medicare and Medicaid Services   (United States)

Author keywords

Anticoagulant; Pharmacoepidemiology; Safety; Thrombin inhibitor; Warfarin

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DABIGATRAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMORBIDITY; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; HEMORRHAGE; INTRACRANIAL HEMORRHAGES; KAPLAN MEIER METHOD; KIDNEY DISEASES; PROPORTIONAL HAZARDS MODEL; RISK; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; STROKE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MEDICARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SOCIOECONOMIC FACTORS; STROKE; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84924034859     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.012061     Document Type: Article

References (34)

1. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(July 20):001927.
2. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. Thromb Res. 2006;118:321-333.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
4. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and meta-analysis. Chest. 2004;126:1938-1945.
5. Product label for Pradaxa (dabigatran etexilate mesylate). http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022512s011lbl.pdf. Accessed July 3, 2012.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
7. Bauer KA. Reversal of antithrombotic agents. Am J Hematol. 2012; 87:119-126.
8. Centers for Medicare & Medicaid Services. Medicare program: general information. http://www.cms.hhs.gov/MedicareGenInfo/Accessed June 26, 2012.
9. Centers for Medicare & Medicaid Services. Prescription drug coverage: general information. http://www.cms.hhs.gov/PrescriptionDrugCovGenIn/Accessed June 26. 2012.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
12. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.
13. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173-180.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 79:516-524.
15. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249-264.
16. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25:1-21.
17. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107.
18. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465-2470.
19. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf. 2008;17:20-26.
20. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10. Stroke. 2005;36:1776-1781.
21. Cunningham AW, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database definition for serious bleeding due to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560-566.
22. Wahl PM, Rodgers K, Schneeweiss S, Gage BF, Butler J, Wilmer C, Nash M, Esper G, Gitlin N, Osborn N, Short LJ, Bohn RL. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19:596-603.
23. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med. 1999;14:555-558.
24. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15:1277-1282.
25. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144:290-296.
26. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99-104.
27. Choma NN, Griffin MR, Huang RL, Mitchel EF Jr, Kaltenbach LA, Gideon P, Stratton SM, Roumie CL. An algorithm to identify incident myocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf. 2009;18:1064-1071.
28. Hill ME, Rosenwaike I. The Social Security Administration's Death Master File: the completeness of death reporting at older ages. Social Security Bulletin 2001/2002; 64:45-51. http://www.socialsecurity.gov/policy/docs/ssb/v64n1/v64n1p45.pdf. Accessed June 26, 2012.
29. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696.
30. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-1274.
31. Sørensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbøl EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Weeke P, Lip GYH, Hansen ML. Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study. BMJ Open. 2013; 3:002758.
32. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GYH. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation. J Am Coll Cardiol. 2013; 61:2264-2273.
33. Beasley N, Thompson A. Medical officer review of application number 22-512 (dabigatran). Center for Drug Evaluation and Research, Food and Drug Administration, August, 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022512Orig1s000MedR.pdfAccessed December 16, 2013.
34. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-2372.